Our data indicate that LHR not only reflects the strength of tumor immune response but also serves as an important marker of tumor metabolic reprogramming, overcoming the limitations of traditional biomarkers such as PD-L1 and tumor mutational burden (TMB). The gene discussed is CD274; the disease is neoplasm.